Last checked at 17 Dec 2018 18:06
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings
Issue of equity
Maryland, USA, 17 December 2018 - MaxCyte (LSE: MXCT) the global cell-based medicines and technology company, announces the issue and allotment of 34,083 new shares of common stock of 0.1 pence ("New Common Stock") to John Johnston, Non-Executive Director of the Company, pursuant to the exercise of share options at an exercise price of 81.5 pence per New Common Stock.
As a result of the above, John Johnston has a beneficial interest of 120,583 Common Stock, representing 0.2% of the issued share capital of the Company and a further 54,617 options over Common Stock.
The New Common Stock will be allocated out of the common stock the subject of the block listing announced on 2 May 2017. The New Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the above will be 51,332,764 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | John Johnston | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Director | |
b) | Initial notification/Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | MaxCyte, Inc. | |
b) | LEI | 54930053YHXULRFCU991 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Ordinary shares of 0.1 pence each
| |
b) | Identification Code | US57777K1060 | |
c) | Nature of the transaction | Exercise of options over Common Stock | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
81.5 pence
| 34,083 | ||
e) | Aggregated information - Aggregated volume - Price | N/A (Single Transaction)
| |
f) | Date of the transaction | 17 December 2018 | |
g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | |
For further information, please contact:
MaxCyte Inc. | |
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer | +1 301 944 1660 |
Nominated Adviser and Broker Panmure Gordon | |
Emma Earl, Freddy Crossley, (Corporate Finance) James Stearns (Corporate Broking) | +44 (0) 20 7886 2500
|
Financial PR Adviser Consilium Strategic Communications | |
Mary-Jane Elliott Chris Welsh Sukaina Virji
| +44 (0)203 709 5700 maxcyte@consilium-comms.com |
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology platform to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.comFor more information, visit www.maxcyte.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.